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The identification of molecular markers with prognostic value in colorectal cancer is a challenging task that is
needed to define therapeutic guidelines. Clinical factors are insufficient to identify those patients with stage II at risk
of relapse or those patients with stage III at low risk. There is a current effort to define a consensus in molecular
subtypes based on expression profiles, which are characterized by a distinctive prognostic outcome. Also several
gene expression signatures based on individual genes have been proposed to predict prognosis, but they show
low consistency and reproducibility. Slattery et al. describe a pathway-based approach to analyze gene expression
differences between normal and colon cancer tissues. The most interesting finding is that having more deregulated
pathways is associated with good prognosis. If these findings are properly validated, new insights into the mechanisms
of colon carcinogenesis may be revealed.
Please see related article: http://dx.doi.org/10.1186/s12916-015-0292-9.
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Colorectal cancer (CRC) is a frequently occurring disease
with high mortality in which prognosis is dramatically
dependent on stage at diagnosis. Adjuvant chemotherapy
is the current standard treatment for stage III but still
controversial in stage II. Recognized clinical risk factors
are insufficient to identify those patients with stage II at
risk of relapse or those patients with stage III at low risk,
leading to potential under or over-treatment [1]. Recently,
multiple efforts have been devoted to characterize the
complex molecular landscape of CRC, aiming to identify
key genes involved in cancer development and prognosis
[2]. This should provide therapeutic targets or prognostic
biomarkers. Mutations in KRAS and TP53 genes are fre-
quent, but lack prognostic value. The subgroup of tumors
showing microsatellite instability (MSI) have better prog-
nosis, but may be resistant to standard 5-fluorouracil adju-
vant therapy. Mutations in BRAF, though less frequent,
may define a subgroup of poor prognosis. Finally, another
subgroup of tumors show the CpG island methylator
phenotype (CIMP). This group overlaps with the MSI and* Correspondence: v.moreno@iconcologia.net
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pendent prognostic value.
Recently, whole genome analyses of tumors have tried
to tackle this topic, either with the analysis of microar-
rays or, more recently, with RNA-seq expression ana-
lysis. The efforts have followed two approaches, either to
define prognostic signatures based on a subset of genes
or to define molecular subtypes, identified with unsuper-
vised modeling strategies, which in a second step are
characterized clinically and attributed a prognostic value
[3]. There is a current effort to define a consensus mo-
lecular subtypes classification, since different studies
have identified diverse numbers of subtypes and genes
related to these subtypes [4]. Similarly, several prognos-
tic profiles based on gene expression have been pro-
posed, with variable predictive ability and not always
with proper validation, which has detracted from their
introduction in clinical practice [5]. Comparisons of
these expression predictors usually show low overlap
when specific genes are analyzed, and this has been
interpreted to mean that the profiles are a random sam-
ple of a higher functional hierarchy that probably is re-
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Slattery et al. [7] describe in BMC Medicine a pathway-
based approach to analyze whole genome expression
changes in colon cancer tissues when compared to normal
adjacent tissue samples. The main conclusion of the study
is that having more deregulated pathways is associated
with good prognosis [7]. This research is innovative in the
analytical approach. The study initially compared RNA-
seq expression data from 175 colon tumors with their
paired adjacent normal mucosa. Differentially expressed
genes found were then assigned to pathways, and the
relevant explanatory variable analyzed was the number
of deregulated genes within pathways. Using a simple
method, each patient was assigned a deregulation score
based on the number of altered genes for each pathway.
Interestingly, they found that having a high score was as-
sociated with better survival in 16 pathways, after adjust-
ing for age, stage, sex, and tumor molecular phenotype
(MSI, TP53, KRAS, and CIMP). The most significant
pathways involved functions related to cell signaling and
growth.
The pathway approach used is an interesting strategy,
since deregulation of different genes could converge in the
same pathway. This allows tumors exhibiting dissimilar
gene expression patterns to achieve a similar phenotype.
In consequence, collapsing genes into pathways could be a
useful tool not only to summarize a large list of genes into
more comprehensive functional entities, but also to clas-
sify a priori molecularly different tumors into subtypes.
From a translational point of view this categorization has
a special relevance, since tumors exhibiting different gene
expression patterns could behave in an analogous way re-
garding treatment response or patient outcome. Indeed,
similar pathway-oriented approaches have been described
to be more useful than those based on expression of indi-
vidual genes [8] and reported to be informative about
prognosis in breast cancer [9].
The authors of this study reported cell cycle as the most
important pathway related to CRC prognosis along with
metabolic pathways and others classically related to colon
carcinogenesis like the Wnt pathway. Other studies on
molecular subtypes using gene expression signatures have
described “epithelial” tumors as highly proliferative and
with better prognosis than tumors with a “mesenchymal”
phenotype [10-12]. It is intriguing that the epithelial-to-
mesenchymal transition (EMT) pathway did not appear as
a relevant pathway in their analysis, which should be re-
lated to poor prognosis. However, the authors identified
TGFB1 as an upstream regulator of genes showing differ-
ential expression using a network analysis. TGFB1 is a
tumor suppressor gene regarding tumor initiation, but
also induces EMT and acts as a promoter of metastasis
[13,14]. This dual role of TGFB1 makes the interpretationof its function difficult, but EMT induced by TGFB1 ex-
pression usually has been related to poor prognosis
[10,13-15]. Also, regarding the functional interpretation of
the data of Slattery’s study, a limitation is that gene ex-
pression in normal tissue adjacent to the tumor has been
shown to be altered, when compared to the expression in
healthy subjects [16]. Probably there is a cross-talk be-
tween tumor and normal adjacent tissue in addition to the
tumor micro-environment cross-talk, and many of the
gene expression signals captured by RNA-seq derive from
stroma and not from the tumor cell [17]. This does not
deny the potential prognostic value of the differences, but
it could modify the interpretation of some of the path-
ways’ effects and the strategy to design targeted therapies.
Another interesting finding revealed in Slattery’s study is
that pathway deregulation is not only related to prognosis
but is also inversely related to stage. Tumors from patients
diagnosed in stage I had more differentially expressed
genes than those from patients with advanced cancer,
though the differences were not statistically significant.
This finding, if confirmed in other studies, opens new
questions related to CRC progression. Why do less ad-
vanced tumors have more differentially expressed genes?
Are metastatic tumors more specialized than early stage
ones and need less altered genes to survive once they have
acquired metastatic potential? Large gene expression
changes in cell cycle observed in stage I and II tumors
could suggest that these tumors are able to proliferate and
grow in size but are unable to develop more sophisticated
functions necessary to invade and disseminate. As the au-
thors propose, perhaps increased gene expression changes
could be destabilizing for the tumor and, in consequence,
responsible for better prognosis.
Despite the interesting findings reported, a major limi-
tation of the study is that the authors have not been able
to provide a validation of their results in an independent
dataset. There are available public datasets on colon can-
cer expression that simultaneously have analyzed tumor
and paired mucosa that can be used to validate differen-
tial expression genes [18], but this dataset is restricted to
stage II tumors and has not published data on prognosis
yet. Other interesting datasets like The Cancer Genome
Atlas (TCGA) consortium study [19] have analyzed very
few normal tissues, and this hinders its utility to validate
results that focus on differences between tumor and nor-
mal tissue such as the specific alterations observed in
Slattery’s study.
Conclusions
In conclusion, this work by Slattery et al. reports a novel
pathway-based approach to predict survival in CRC pa-
tients. This novel strategy could overcome gene expres-
sion signature approaches. However, although promising,
these findings need further validation. If the prognostic
Moreno and Sanz-Pamplona BMC Medicine  (2015) 13:76 Page 3 of 3value of these pathway scores can be replicated in inde-
pendent datasets, the findings would represent a major
contribution and warrant a novel view in understanding
gene deregulation observed in colon cancer.
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